Details

Autor(en) / Beteiligte

• Garcia-Portilla, Maria P
• Garcia-Alvarez, Leticia
• Sarramea, Fernando
• Galvan, Gonzalo
• Diaz-Mesa, Eva
• Bobes-Bascaran, Teresa
• Al-Halabi, Susana
• Elizagarate, Edorta
• Iglesias, Celso
• Saiz Martínez, Pilar A
• Bobes, Julio

Titel

It is feasible and effective to help patients with severe mental disorders to quit smoking: An ecological pragmatic clinical trial with transdermal nicotine patches and varenicline

Ist Teil von

• Schizophrenia research, 2016-10, Vol.176 (2-3), p.272-280

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Despite the proven association between smoking and high rates of medical morbidity and reduced life expectancy in people with severe mental disorders (SMD), their smoking rates do not decline as they do in the general population. We carried out a non-randomized, open-label, prospective, 9-month follow-up multicentre trial to investigate the clinical efficacy, safety and tolerability of a 12-week smoking cessation programme for patients with SMD in the community under real-world clinical conditions. Eighty-two adult outpatients with schizophrenic/bipolar disorder smoking ≥ 15 cigarettes/day were assigned by shared decision between doctors and patients to transdermal nicotine patches (TNP) [36(46.2%)] or varenicline [39(50%)]. Short-term efficacy : The 12-week 7-day smoking cessation (self-reported cigarettes/day = 0 and breath carbon monoxide levels ≤ 9 ppm) prevalence was 49.3%, without statistically significant differences between medications (TNP 50.0% vs varenicline 48.6%, chi-square = 0.015, p = 1.000). Long-term efficacy : At weeks 24 and 36, 41.3 and 37.3% of patients were abstinent, with no statistically significant differences between treatments. Safety and Tolerability : no patients made suicide attempts/required hospitalization. There was no worsening on the psychometric scales. Patients significantly increased weight [TNP 1.1(2.8) vs varenicline 2.5(3.3), p = 0.063], without significant changes in vital signs/laboratory results, except significant decreases in alkaline phosphatase and low-density lipoprotein-cholesterol levels in the varenicline group. Patients under varenicline more frequently presented nausea/vomiting ( p < 0.0005), patients under TNP experienced skin reactions more frequently ( p = 0.002). Three patients under varenicline had elevated liver enzymes. In conclusion, we have demonstrated that in real-world clinical settings it is feasible and safe to help patients with stabilized severe mental disorders to quit smoking.